EFFECT OF VITAMIN D SUPPLEMENTATION ON THE VENTRICULAR DEFORMATION RATE (STRAIN RATE) IN PATIENTS WITH HEART FAILURE WITH PRESERVED OR MODERATELY REDUCED EYECTION FRACTIO

Sergio Aleman0 个研究点目标入组 102 人开始时间: 2018年7月17日最近更新: 2019年12月10日

适应症

试验速览

暂无简介。

•A.- Heart failure with preserved or moderately reduced ejection fraction (HFp / HFmr) that meet diagnostic criteria according to the Clinical Guidelines of the European Society of Cardiology :
•- At least one episode of symptoms and / or signs of heart failure in the last 6 months.
•- Demonstrated ejection fraction> 40% (including clinical entities of preserved and moderately reduced ejection fraction).
•- Elevation natriuretic peptides: NTproBNP> 125 pg / ml or
•BNP> 35 pg / ml
•- Demonstration of structural heart disease: Left ventricular hypertrophy / left atrial enlargement / diastolic dysfunction
•B.- Vitamin D deficiency demonstrated with serum levels <20 ng / mL (vitamin deficit).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 102

•- Active treatment with Vitamin D supplements.
•- Advanced chronic kidney disease with glomerular filtration <30 ml / min / 1.73m2.
•- Malabsorptive syndromes that interfere with the absorption of vitamin D.
•- Diseases that affect the metabolism of calcium and phosphorus.
•- Hypercalcemia (serum calcium corrected with albumin> 10.5 mg / dL).
•- Severe valvular disease of any origin.
•- Atrial fibrillation.
•- Severe psychosocial problems (dementia, alcoholism, any consumption of toxics, psychiatric disorders or moderate or severe cognitive impairment of any origin that prevent the patient's follow-up or adherence to the study).

发起方

Sergio Aleman